Cambazard F
C.H.U. de Saint Etienne, Department of Dermatology, France.
J Eur Acad Dermatol Venereol. 1998 Sep;11 Suppl 1:S20-7; discussion S28-9.
Velac, a new gel formulation containing both tretinoin (0.025%) and clindamycin phosphate (1.2%), is effective in acne vulgaris using a once daily application. The single formulation enhances compliance in young patients and improves the therapeutic results. Treatment with Velac was found to be more effective than tretinoin alone in inflamed lesions and at least comparable in open and closed comedones. In two of the three studies the overall acne severity grade was significantly more reduced when compared with tretinoin. Velac is also more effective than clindamycin alone in the treatment of the non-inflamed lesions. In the two multicentre studies the reduction of the overall acne severity grade was also more favourable for the new gel formulation. A more rapid response occurred with Velac than with either component used (clindamycin or tretinoin) alone.
维乐乳膏（Velac）是一种新的凝胶制剂，含有维甲酸（0.025%）和磷酸克林霉素（1.2%），每天使用一次对寻常痤疮有效。单一制剂提高了年轻患者的依从性并改善了治疗效果。研究发现，维乐乳膏治疗在炎症性皮损方面比单独使用维甲酸更有效，在开放性和闭合性粉刺方面至少相当。在三项研究中的两项中，与维甲酸相比，总体痤疮严重程度分级显著降低。维乐乳膏在治疗非炎症性皮损方面也比单独使用克林霉素更有效。在两项多中心研究中，新凝胶制剂在总体痤疮严重程度分级的降低方面也更有利。维乐乳膏比单独使用任何一种成分（克林霉素或维甲酸）产生的反应更快。
